Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Klimawandel und Gesundheit: Was Sie in der Hausarztpraxis wissen müssen und tun können

Die Folgen des Klimwandels haben einen direkten Einfluss auf die Primärversorgung in Deutschland: Hitzeschutz insbesondere bei älteren Patienten, die Zunahme von Infektionen und die Verlängerung der Allergiesesaison spielen medizinisch eine bedeutsame Rolle. Aber auch in der Prävention und der Aufklärung der Patienten kommt den Hausärztinnen und -ärzten eine besondere Rolle zu. Direkt aus der Praxis berichtet im Live-Webinar am 13. Mai von 18 bis 19 Uhr unser Experte Dr. med. Robin Maitra.
Erweiterte Suche
Anmelden
nach oben
Drugs
Erschienen in: Drugs 14/2015

01.09.2015 | Adis Drug Evaluation

Roflumilast: A Review in COPD

verfasst von: Karly P. Garnock-Jones

Erschienen in: Drugs | Ausgabe 14/2015

Einloggen, um Zugang zu erhalten

Abstract

Roflumilast (Daliresp®, Daxas®) is a selective phosphodiesterase 4 (PDE4) inhibitor that decreases systemic and pulmonary inflammation and improves disease symptoms in patients with severe chronic obstructive pulmonary disease (COPD). This article reviews the pharmacological properties of roflumilast and its clinical efficacy and tolerability in patients with COPD. Roflumilast is an effective treatment in patients with moderate to severe COPD; it improves lung function and is generally associated with a lower risk of exacerbation, particularly in patients with more severe disease and/or chronic bronchitis, cough and sputum. It is generally well tolerated; the most common adverse event was diarrhoea. While associated with an increased risk of psychiatric adverse events and weight loss, roflumilast is not associated with an increased risk of respiratory disease and infection, and may decrease the risk of cardiovascular adverse events. Roflumilast is a useful addition to the treatment options for patients with COPD.
Literatur
1.
Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategies for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. 2015. http://​www.​goldcopd.​org. Accessed 25 May 2015.
2.
3.
Rabe KF. Update on roflumilast, a phosphodiesterase 4 inhibitor for the treatment of chronic obstructive pulmonary disease. Br J Pharmacol. 2011;163(1):53–67.PubMedCentralCrossRefPubMed
4.
Giembycz MA, Maurice DH. Cyclic nucleotide-based therapeutics for chronic obstructive pulmonary disease. Curr Opin Pharmacol. 2014;16(Suppl C):89–107.CrossRefPubMed
5.
6.
Hatzelmann A, Schudt C. Anti-inflammatory and immunomodulatory potential of the novel PDE4 inhibitor roflumilast in vitro. J Pharmacol Exp Ther. 2001;297(1):267–79.PubMed
7.
Buenestado A, Grassin-Delyle S, Guitard F, et al. Roflumilast inhibits the release of chemokines and TNF-alpha from human lung macrophages stimulated with lipopolysaccharide. Br J Pharmacol. 2012;165(6):1877–90.PubMedCentralCrossRefPubMed
8.
Buenestado A, Chaumais MC, Grassin-Delyle S, et al. Roflumilast inhibits lipopolysaccharide-induced tumor necrosis factor-alpha and chemokine production by human lung parenchyma. PLoS One. 2013;8(9):e74640.PubMedCentralCrossRefPubMed
9.
Victoni T, Gleonnec F, Lanzetti M, et al. Roflumilast N-oxide prevents cytokine secretion induced by cigarette smoke combined with LPS through JAK/STAT and ERK1/2 inhibition in airway epithelial cells. PLoS One. 2014;9(1):e85243.PubMedCentralCrossRefPubMed
10.
Vecchio D, Acquaviva A, Arezzini B, et al. Downregulation of NOX4 expression by roflumilast N-oxide reduces markers of fibrosis in lung fibroblasts. Mediators Inflamm. 2013;2013:745984.PubMedCentralCrossRefPubMed
11.
Höhne K, Schließmann SJ, Kirschbaum A, et al. Roflumilast-N-oxide induces surfactant protein expression in human alveolar epithelial cells type II. PLoS One. 2012;7(7):e38369.PubMedCentralCrossRefPubMed
12.
Milara J, Armengot M, Banuls P, et al. Roflumilast N-oxide, a PDE4 inhibitor, improves cilia motility and ciliated human bronchial epithelial cells compromised by cigarette smoke in vitro. Br J Pharmacol. 2012;166(8):2243–62.PubMedCentralCrossRefPubMed
13.
Milara J, Peiro T, Serrano A, et al. Roflumilast N-oxide inhibits bronchial epithelial to mesenchymal transition induced by cigarette smoke in smokers with COPD. Pulm Pharmacol Ther. 2014;28(2):138–48.CrossRefPubMed
14.
Milara J, Lluch J, Almudever P, et al. Roflumilast N-oxide reverses corticosteroid resistance in neutrophils from patients with chronic obstructive pulmonary disease. J Allergy Clin Immunol. 2014;134(2):314–22.CrossRefPubMed
15.
Milara J, Morell A, Ballester B, et al. Roflumilast improves corticosteroid resistance COPD bronchial epithelial cells stimulated with toll like receptor 3 agonist. Respir Res. 2015;16:12.PubMedCentralCrossRefPubMed
16.
Hatzelmann A, Morcillo EJ, Lungarella G, et al. The preclinical pharmacology of roflumilast: a selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease. Pulm Pharmacol Ther. 2010;23(4):235–56.CrossRefPubMed
17.
Martorana PA, Beume R, Lucattelli M, et al. Roflumilast fully prevents emphysema in mice chronically exposed to cigarette smoke. Am J Respir Crit Care Med. 2005;172(7):848–53.CrossRefPubMed
18.
Hohlfeld JM, Schoenfeld K, Lavae-Mokhtari M, et al. Roflumilast attenuates pulmonary inflammation upon segmental endotoxin challenge in healthy subjects: a randomized placebo-controlled trial. Pulm Pharmacol Ther. 2008;21(4):616–23.CrossRefPubMed
19.
Grootendorst DC, Gauw SA, Verhoosel RM, et al. Reduction in sputum neutrophil and eosinophil numbers by the PDE4 inhibitor roflumilast in patients with COPD. Thorax. 2007;62(12):1081–7.PubMedCentralCrossRefPubMed
20.
Marquez-Martin E, Ortega F, Campano E, et al. Reduction in systemic inflammation by the PDE4 inhibitor roflumilast in patients with COPD [abstract no. 732A]. Chest. 2013;144(4 MeetingAbstracts). doi:10.​1378/​chest.​1703911.
21.
Huennemeyer A, Nassr N, Bredenbröker D, et al. Supra-therapeutic doses of roflumilast have no effect on cardiac repolarization in healthy subjects. Expert Opin Drug Saf. 2011;10(4):509–19.CrossRefPubMed
22.
Bethke TD, Lahu G. High absolute bioavailability of the new oral phosphodiesterase-4 inhibitor roflumilast. Int J Clin Pharmacol Ther. 2011;49(1):51–7.CrossRefPubMed
23.
Hauns B, Hermann R, Hunnemeyer A, et al. Investigation of a potential food effect on the pharmacokinetics of roflumilast, an oral, once-daily phosphodiesterase 4 inhibitor, in healthy subjects. J Clin Pharmacol. 2006;46(10):1146–53.CrossRefPubMed
24.
Bethke TD, Huennemeyer A, Lahu G, et al. Chronopharmacology of roflumilast: a comparative pharmacokinetic study of morning versus evening administration in healthy adults. Chronobiol Int. 2010;27(9–10):1843–53.CrossRefPubMed
25.
de Mey C, Nassr N, Lahu G. No relevant cardiac, pharmacokinetic or safety interactions between roflumilast and inhaled formoterol in healthy subjects: an open-label, randomised, actively controlled study. BMC Clin Pharmacol. 2011;11:7.PubMedCentralCrossRefPubMed
26.
McCracken N, Lahu G, Bethke TD. Lack of pharmacokinetic and pharmacodynamic interactions of roflumilast with (R, S)-warfarin in healthy adult subjects. Int J Clin Pharmacol Ther. 2011;49(6):388–96.CrossRefPubMed
27.
Lee SD, Hui DS, Mahayiddin AA, et al. Roflumilast in Asian patients with COPD: a randomized placebo-controlled trial. Respirology. 2011;16(8):1249–57.CrossRefPubMed
28.
O’Donnell DE, Bredenbroker D, Brose M, et al. Physiological effects of roflumilast at rest and during exercise in COPD. Eur Respir J. 2012;39(5):1104–12.CrossRefPubMed
29.
Zheng J, Yang J, Zhou X, et al. Roflumilast for the treatment of COPD in an Asian population: a randomized, double-blind, parallel-group study. Chest. 2014;145(1):44–52.CrossRefPubMed
30.
Rabe KF, Bateman ED, O’Donnell D, et al. Roflumilast - an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trial. Lancet. 2005;366(9485):563–71.CrossRefPubMed
31.
Calverley PM, Rabe KF, Goehring UM, et al. Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet. 2009;374(9691):685–94.CrossRefPubMed
32.
Calverley PM, Sanchez-Toril F, McIvor A, et al. Effect of 1-year treatment with roflumilast in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2007;176(2):154–61.CrossRefPubMed
33.
National Institute for Health and Clinical Excellence. Premeeting briefing: roflumilast for the management of chronic obstructiv pulmonary disease. 2011. http://​www.​nice.​org.​uk. Accessed 29 Jul 2015.
34.
Takeda. OPUS study: effect of roflumilast on exacerbation rate in patients with chronic obstructive pulmonary disease (BY217/M2-111) [NCT00076089]. 2012. http://​www.​clinicaltrials.​gov. Accessed 29 Jul 2015.
35.
Creanga D, Bredenbroeker D, Brose M, et al. Effect of roflumilast treatment on dyspnea in patients with chronic obstructive pulmonary disease [abstract no. 97670]. J Hosp Med. 2012;7(Suppl 2):127.
36.
Creanga D, Bredenbroeker D, Brose M, et al. Effect of roflumilast treatment on health-related quality of life in patients with chronic obstructive pulmonary disease [abstract no. 97664]. J Hosp Med. 2012;7(Suppl 2):121.
37.
Rennard SI, Calverley PM, Goehring UM, et al. Reduction of exacerbations by the PDE4 inhibitor roflumilast: the importance of defining different subsets of patients with COPD. Respir Res. 2011;12:18.PubMedCentralCrossRefPubMed
38.
Hanania NA, Calverley PM, Dransfield MT, et al. Pooled subpopulation analyses of the effects of roflumilast on exacerbations and lung function in COPD. Respir Med. 2014;108(2):366–75.CrossRefPubMed
39.
Bateman ED, Rabe KF, Calverley PM, et al. Roflumilast with long-acting beta2-agonists for COPD: influence of exacerbation history. Eur Respir J. 2011;38(3):553–60.CrossRefPubMed
40.
Wedzicha JA, Rabe KF, Martinez FJ, et al. Efficacy of roflumilast in the COPD frequent exacerbator phenotype. Chest. 2013;143(5):1302–11.CrossRefPubMed
41.
Rennard SI, Sun SX, Tourkodimitris S, et al. Roflumilast and dyspnea in patients with moderate to very severe chronic obstructive pulmonary disease: a pooled analysis of four clinical trials. Int J Chron Obstruct Pulmon Dis. 2014;9:657–73.PubMedCentralCrossRefPubMed
42.
Fabbri LM, Calverley PM, Izquierdo-Alonso JL, et al. Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials. Lancet. 2009;374(9691):695–703.CrossRefPubMed
43.
Martinez FJ, Calverley PMA, Goehring U-M, et al. Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trial. Lancet. 2015;385(9971):857–66.CrossRefPubMed
44.
Chong J, Leung B, Poole P. Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2013;11:Cd002309.PubMed
45.
Oba Y, Lone NA. Efficacy and safety of roflumilast in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. Ther Adv Respir Dis. 2013;7(1):13–24.CrossRefPubMed
46.
Yan JH, Gu WJ, Pan L. Efficacy and safety of roflumilast in patients with stable chronic obstructive pulmonary disease: a meta-analysis. Pulm Pharmacol Ther. 2014;27(1):83–9.CrossRefPubMed
47.
Pan L, Guo YZ, Zhang B, et al. Does roflumilast improve dyspnea in patients with chronic obstructive pulmonary disease? A meta-analysis. J Thorac Dis. 2013;5(4):422–9.PubMedCentralPubMed
48.
Wouters EFM, Teichmann P, Brose M, et al. Effects of roflumilast, a phosphodiesterase 4 inhibitor, on body composition in chronic obstructive pulmonary disease [abstract]. Am J Respir Crit Care Med. 2010;181:A4473.
49.
Calverley PMA, Fabbri LM, Rabe KF, et al. Roflumilast in the treatment of COPD: a pooled safety analysis [abstract no. P4001]. In: The European Respiratory Society Annual Congress; 2010.
50.
White WB, Cooke GE, Kowey PR, et al. Cardiovascular safety in patients receiving roflumilast for the treatment of COPD. Chest. 2013;144(3):758–65.CrossRefPubMed
51.
Ferguson G, Hanania N, Goehring UM, et al. Respiratory-associated adverse events in the roflumilast COPD safety pool [abstract]. Chest. 2012;142(4 Suppl 1):665A.CrossRef
52.
Solem CT, Sun SX, Sudharshan L, et al. Exacerbation-related impairment of quality of life and work productivity in severe and very severe chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2013;8:641–52.PubMedCentralCrossRefPubMed
53.
White WB, Kowey PR, Zhu H. Evaluation of major adverse cardiac events (MACE) in a one-year, placebo-controlled study of roflumilast in patients with chronic obstructive pulmonary disease (COPD): rationale and design [abstract no. F68]. Am J Respir Crit Care Med. 2013;187:A1484.CrossRef
54.
55.
Samyshkin Y, Kotchie RW, Mork AC, et al. Cost-effectiveness of roflumilast as an add-on treatment to long-acting bronchodilators in the treatment of COPD associated with chronic bronchitis in the United Kingdom. Eur J Health Econ. 2014;15(1):69–82.PubMedCentralCrossRefPubMed
56.
Hertel N, Kotchie RW, Samyshkin Y, et al. Cost-effectiveness of available treatment options for patients suffering from severe COPD in the UK: a fully incremental analysis. Int J Chron Obstruct Pulmon Dis. 2012;7:183–99.PubMedCentralCrossRefPubMed
57.
Nowak D, Ehlken B, Kotchie R, et al. Roflumilast in combination with long-acting bronchodilators in the management of patients with severe and very severe COPD. A cost-effectiveness analysis for Germany. Dtsch Med Wochenschr. 2013;138(4):119–25.CrossRefPubMed
58.
Samyshkin Y, Schlunegger M, Haefliger S, et al. Cost-effectiveness of roflumilast in combination with bronchodilator therapies in patients with severe and very severe COPD in Switzerland. Int J Chron Obstruct Pulmon Dis. 2013;8:79–87.PubMedCentralCrossRefPubMed
Metadaten
Titel
Roflumilast: A Review in COPD
verfasst von
Karly P. Garnock-Jones
Publikationsdatum
01.09.2015
Verlag
Springer International Publishing
Erschienen in
Drugs / Ausgabe 14/2015
Print ISSN: 0012-6667
Elektronische ISSN: 1179-1950
DOI
https://doi.org/10.1007/s40265-015-0463-1

Weitere Artikel der Ausgabe 14/2015

Drugs 14/2015 Zur Ausgabe

Review Article

Anticancer Drug Delivery: An Update on Clinically Applied Nanotherapeutics

AdisInsight Report

Brexpiprazole: First Global Approval

Current Opinion

Escalation and De-escalation of Therapy in COPD: Myths, Realities and Perspectives

Review Article

Direct Oral Anticoagulants for the Prevention of Stroke in Patients with Nonvalvular Atrial Fibrillation: Understanding Differences and Similarities

Adis Drug Evaluation

Eliglustat: A Review in Gaucher Disease Type 1

Leading Article

New and Emerging Agents for the Treatment of Hemophilia: Focus on Extended Half-Life Recombinant Clotting Proteins